October 24, 2023 ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
Read Article
October 17, 2023 ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
Read Article
September 19, 2023 ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
Read Article
May 24, 2023 ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
Read Article
April 25, 2023 ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
Read Article
January 17, 2023 ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
Read Article
November 15, 2022 ImmunOs Therapeutics’ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
Read Article
October 17, 2022 ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
Read Article
October 4, 2022 ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors.
Read Article
June 7, 2022 ImmunOs Therapeutics Raises $74 Million Series B Financing Round.
Read Article
December 6, 2021 ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer.
Read Article
November 15, 2021 ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro.
Read Article
October 13, 2021 ImmunOs Therapeutics AG Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC).
Read Article
September 30, 2021 ImmunOs Therapeutics AG today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.
Read Article
September 1, 2021 ImmunOs Therapeutics AG Appoints Seasoned Exec Jeffrey Abbey as Chief Operating Officer and High-Caliber Clinical and Scientific Advisors.
Read Article
April 12, 2021 ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases.
Read Article
November 13, 2020 ImmunOs Therapeutics AG Presents Data from their iosH2 Program at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting.
Read Article
December 10, 2019 ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials.
Read Article
September 18, 2018 UZH Life Sciences Fund and Schroder Adveq Invest in ImmunOs Therapeutics AG to Support Advancement of their Immunotherapy Platform for Cancer.
Read Article